Importantly, some drugs may reconstitute the capabilities of sMICA-inhibited cytotoxicity of CD8+ and NK cells [23, 24], thus further highlights the potential of NKG2D + T CD8+ and NK cell-mediated immunotherapeutic interventions in MM [24, 25, 26]. This evidence concerns the gene KLRK1 and Miyoshi myopathy.